Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
Gb8hG61wj8VAfrEh
Listen
